References
- Nomura N, Mitsuyama J, Furuta Y, Yamada H, Nakata M, Fukuda T, et al. In vitro and in vivo antibacterial activities of pazufloxacin mesilate, a new injectable quinolone. Jpn J Antibiot. 2002;55:412–39.
- Minami S, Hattori R, Matsuda A. Pharmacological properties and expected clinical role of an injectable new quinolone antibiotic, pazufloxacin mesilate. Folia Pharmacol Jpn. 2003;122:161–78.
- Wang XG, Miao J, Liang DR, Yu Q, Liang MZ, Zhang SH. Clinical pharmacokinetics/pharmacodynamics study on pazufloxacin methanesulphonate injection. Sichuan Da Xue Xue Bao Yi Xue Ban (Journal of Sichuan University Medical Science Edition). 2009;40:689–93.
- Vora A. Pazufloxacin. J Assoc Physicians India. 2009;57:722–23.
- Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009;31:107–46.
- Ikawa K, Nakashima A, Morikawa N, Ikeda K, Murakami Y, Ohge H, et al. Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment. Antimicrob Agents Chemother. 2011;55:5609–15.
- Watabe S, Yokoyama Y, Nakazawa K, Shinozaki K, Hiraoka R, Takeshita K, et al. Simultaneous measurement of pazufloxacin, ciprofloxacin, and levofloxacin in human serum by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878:1555–61.
- Hasegawa T, Nadai M, Haghgoo S, Yamaki K, Takagi K, Nabeshima T. Influence of a newly developed quinolone, T-3761, on pharmacokinetics of theophylline in rats. Antimicrob Agents Chemother. 1995;39:2138–40.
- Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn. 1981;4:879–85.
- Craig WA. The role of pharmacodynamics in effective treatment of community-acquired pathogens. Adv Stud Med. 2002;2:126–34.
- Wispelwey B. Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones. Clin Infect Dis. 2005;41(Suppl 2):S127–35.
- Boselli E, Breilh D, Rimmelé T, Djabarouti S, Saux MC, Chassard D, et al. Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. Crit Care Med. 2005;33:104–9.
- Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it’s not just for mice anymore. Clin Infect Dis. 2007;44:79–86.
- Fish DN. Evaluation of gatifloxacin pharmacokinetics and pharmacodynamics in severely ill adults in a medical intensive care unit. Int J Antimicrob Agents. 2007;29:715–23.
- Muratani T, Inoue M, Mitsuhashi S. In vitro activity of T-3761, a new fluoroquinolone. Antimicrob Agents Chemother. 1992;36:2293–303.
- Parry MF, Smego DA, Digiovanni MA. Hepatobiliary kinetics and excretion of ciprofloxacin. Antimicrob Agents Chemother. 1988;32:982–85.
- Hayton WL, Vlahov V, Bacracheva N, Viachki I, Portmann R, Muirhead G, et al. Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients. Antimicrob Agents Chemother. 1990;34:2375–80.
- Ober MC, Hoppe-Tichy T, Koninger J, Schunter O, Sonntag HG, Weigand MA, et al. Tissue penetration of moxifloxacin into human gallbladder wall in patients with biliary tract infections. J Antimicrob Chemother. 2009;64:1091–5.